Published in FASEB J on October 26, 2012
Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol (2013) 1.76
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med (2014) 1.67
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell (2013) 1.29
Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med (2013) 1.04
Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis. EBioMedicine (2014) 0.95
CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol (2014) 0.94
Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol (2014) 0.94
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell (2016) 0.92
Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol Res (2014) 0.92
Tgf-β1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS One (2013) 0.90
Stabilizing rescued surface-localized δf508 CFTR by potentiation of its interaction with Na(+)/H(+) exchanger regulatory factor 1. Biochemistry (2014) 0.88
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther (2014) 0.84
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev Precis Med Drug Dev (2016) 0.82
Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly. J Mol Biol (2014) 0.82
A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. FASEB J (2015) 0.81
Precision Genomic Medicine in Cystic Fibrosis. Clin Transl Sci (2015) 0.80
Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int (2015) 0.79
Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. Am J Physiol Lung Cell Mol Physiol (2014) 0.78
Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect (2015) 0.78
Pharmacological correction of misfolding of ABC proteins. Drug Discov Today Technol (2014) 0.78
A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. Am J Respir Cell Mol Biol (2014) 0.77
Targeted proteomic quantitation of the absolute expression and turnover of cystic fibrosis transmembrane conductance regulator in the apical plasma membrane. J Proteome Res (2014) 0.77
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry. Chembiochem (2015) 0.76
Two Small Molecules Restore Stability to a Sub-population of the Cystic Fibrosis Transmembrane conductance Regulator with the Predominant Disease-causing Mutation. J Biol Chem (2017) 0.75
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front Pharmacol (2016) 0.75
Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds. Br J Pharmacol (2017) 0.75
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability. Cell Mol Life Sci (2016) 0.75
PharmGKB summary: very important pharmacogene information for CFTR. Pharmacogenet Genomics (2015) 0.75
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 8.47
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A (2009) 5.72
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A (2011) 3.87
The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol (2004) 3.16
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A (2008) 3.08
Biosynthesis and degradation of CFTR. Physiol Rev (1999) 2.87
Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem (2000) 2.54
Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat Struct Biol (1998) 2.49
Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros (2012) 2.25
Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol (2006) 2.17
CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med (2011) 1.99
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci (2010) 1.87
Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences. Cell (2012) 1.81
Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell (2012) 1.73
Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. J Biol Chem (1996) 1.66
Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J Biol Chem (2008) 1.62
The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem (2010) 1.55
Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sci (2009) 1.50
Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. J Biol Chem (2002) 1.44
MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model (2008) 1.37
Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic (2008) 1.34
Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. J Mol Biol (2010) 1.31
Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore. Biochemistry (2009) 1.28
Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. J Membr Biol (1999) 1.27
Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am (2000) 1.26
Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. Biochemistry (1997) 1.25
Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci (2010) 1.25
Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model (2010) 1.21
Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity. J Biol Chem (1996) 1.21
Restoration of domain folding and interdomain assembly by second-site suppressors of the DeltaF508 mutation in CFTR. FASEB J (2010) 1.18
Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. J Mol Biol (2012) 1.18
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des (2010) 1.17
The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. PLoS One (2010) 1.17
The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface. Biochemistry (2010) 1.09
Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet (2009) 1.08
Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol (2011) 1.07
Thermally unstable gating of the most common cystic fibrosis mutant channel (ΔF508): "rescue" by suppressor mutations in nucleotide binding domain 1 and by constitutive mutations in the cytosolic loops. J Biol Chem (2011) 1.04
New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation. J Chem Inf Model (2012) 1.03
Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity. Biochemistry (2012) 1.01
Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein. J Med Chem (2012) 0.86
Comparison of the CFTR mutation spectrum in three cohorts of patients of Celtic origin from Brittany (France) and Ireland. Hum Mutat (2003) 0.78
High incidence of delta I507 mutation of the CFTR gene in a limited area of the north west of France. J Med Genet (1995) 0.77
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A (2008) 3.08
Methods for obtaining and analyzing whole chloroplast genome sequences. Methods Enzymol (2005) 2.86
Ab initio RNA folding by discrete molecular dynamics: from structure prediction to folding mechanisms. RNA (2008) 2.86
Eris: an automated estimator of protein stability. Nat Methods (2007) 2.78
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Engineered allosteric activation of kinases in living cells. Nat Biotechnol (2010) 2.44
The Chlamydomonas reinhardtii plastid chromosome: islands of genes in a sea of repeats. Plant Cell (2002) 2.36
Emergence of protein fold families through rational design. PLoS Comput Biol (2006) 2.35
Identifying the basal angiosperm node in chloroplast genome phylogenies: sampling one's way out of the Felsenstein zone. Mol Biol Evol (2005) 2.23
Ab initio folding of proteins with all-atom discrete molecular dynamics. Structure (2008) 2.22
Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell (2004) 2.21
The First Nucleotide Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is a Site of Stable Nucleotide Interaction, whereas the Second Is a Site of Rapid Turnover. J Biol Chem (2002) 2.20
Expression pattern shifts following duplication indicative of subfunctionalization and neofunctionalization in regulatory genes of Arabidopsis. Mol Biol Evol (2005) 2.18
Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol (2006) 2.17
Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell (2005) 2.13
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
iFoldRNA: three-dimensional RNA structure prediction and folding. Bioinformatics (2008) 2.03
The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke (2011) 1.90
RNA-Puzzles: a CASP-like evaluation of RNA three-dimensional structure prediction. RNA (2012) 1.88
F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. Biochim Biophys Acta (2006) 1.87
Functional fingerprints of folds: evidence for correlated structure-function evolution. J Mol Biol (2003) 1.80
Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J (2011) 1.79
COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J Cell Biol (2004) 1.70
Molecular dynamics simulation of the SH3 domain aggregation suggests a generic amyloidogenesis mechanism. J Mol Biol (2002) 1.66
Modeling backbone flexibility improves protein stability estimation. Structure (2007) 1.65
Automated minimization of steric clashes in protein structures. Proteins (2011) 1.64
Multiscale modeling of nucleosome dynamics. Biophys J (2006) 1.63
Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J Biol Chem (2008) 1.62
On the significance of an RNA tertiary structure prediction. RNA (2010) 1.61
Direct molecular dynamics observation of protein folding transition state ensemble. Biophys J (2002) 1.55
EST clustering error evaluation and correction. Bioinformatics (2004) 1.54
Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem (2004) 1.54
The interface of protein structure, protein biophysics, and molecular evolution. Protein Sci (2012) 1.54
Mechanism for the alpha-helix to beta-hairpin transition. Proteins (2003) 1.51
Computational design of a PAK1 binding protein. J Mol Biol (2010) 1.51
Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway. J Biol Chem (2002) 1.50
The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2004) 1.46
Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem (2009) 1.46
Association of interleukin-1 gene cluster polymorphisms with ischemic stroke in a Chinese population. Neurol India (2006) 1.45
Can contact potentials reliably predict stability of proteins? J Mol Biol (2004) 1.44
F-wave latencies in patients with diabetes mellitus. Muscle Nerve (2014) 1.42
Simple but predictive protein models. Trends Biotechnol (2005) 1.39
Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol (2009) 1.37
MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model (2008) 1.37
Gene capture prediction and overlap estimation in EST sequencing from one or multiple libraries. BMC Bioinformatics (2005) 1.35
Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic (2008) 1.34
The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. J Physiol (2006) 1.34
Native-like RNA tertiary structures using a sequence-encoded cleavage agent and refinement by discrete molecular dynamics. J Am Chem Soc (2009) 1.33
CFTR (ABCC7) is a hydrolyzable-ligand-gated channel. Pflugers Arch (2006) 1.32
Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. J Mol Biol (2010) 1.31
Folding Trp-cage to NMR resolution native structure using a coarse-grained protein model. Biophys J (2004) 1.29
The PDZ-binding chloride channel ClC-3B localizes to the Golgi and associates with cystic fibrosis transmembrane conductance regulator-interacting PDZ proteins. J Biol Chem (2002) 1.28
Fast complementation of split fluorescent protein triggered by DNA hybridization. Proc Natl Acad Sci U S A (2006) 1.26
The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology (2004) 1.25
Common dynamical signatures of familial amyotrophic lateral sclerosis-associated structurally diverse Cu, Zn superoxide dismutase mutants. Proc Natl Acad Sci U S A (2006) 1.25
Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p/EDEM and the Cdc48 protein complex in yeast. Mol Biol Cell (2004) 1.25
Imprint of evolution on protein structures. Proc Natl Acad Sci U S A (2004) 1.24
Dynamical roles of metal ions and the disulfide bond in Cu, Zn superoxide dismutase folding and aggregation. Proc Natl Acad Sci U S A (2008) 1.23
Light regulation of protein dimerization and kinase activity in living cells using photocaged rapamycin and engineered FKBP. J Am Chem Soc (2010) 1.23
The path of DNA in the kinetochore. Curr Biol (2006) 1.22
Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model (2010) 1.21
Three-dimensional RNA structure refinement by hydroxyl radical probing. Nat Methods (2012) 1.20
Restoration of domain folding and interdomain assembly by second-site suppressors of the DeltaF508 mutation in CFTR. FASEB J (2010) 1.18
Reconstruction of the src-SH3 protein domain transition state ensemble using multiscale molecular dynamics simulations. J Mol Biol (2005) 1.18
Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. J Mol Biol (2012) 1.18
Protein folding: then and now. Arch Biochem Biophys (2007) 1.18
Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput Biol (2005) 1.17
Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Comput Biol (2010) 1.17
Folding of Cu, Zn superoxide dismutase and familial amyotrophic lateral sclerosis. J Mol Biol (2003) 1.17
BiPS, a photocleavable, isotopically coded, fluorescent cross-linker for structural proteomics. Mol Cell Proteomics (2008) 1.17
Principles for understanding the accuracy of SHAPE-directed RNA structure modeling. Biochemistry (2013) 1.16
iFold: a platform for interactive folding simulations of proteins. Bioinformatics (2006) 1.15
Topological determinants of protein domain swapping. Structure (2006) 1.15
Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J Cell Sci (2007) 1.15